Ajax, aiming for a better JAK drug, raises $95M to begin first tests
BioPharma Drive: Drug Pricing
MAY 13, 2024
Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.
Let's personalize your content